Interventional Cardiology, from MedMarket Diligence, LLC

Interventional Cardiology, from MedMarket Diligence, LLC Coverage of technology and clinical practice developments in interventional cardiology, from the Market and Technology Reports analysis and other ongoing research from MedMarket Diligence, LLC http://mediligence.com/rpt/interventional-cardiology.htm Business/Business_Services/Consulting/Medical_and_Life_Sciences Copyright 2008, MedMarket Diligence, LLC en-us Mon, 16 Nov 2009 12:15:14 -0800 pjd@mediligence.com (Patrick Driscoll) Mon, 16 Nov 2009 12:00:10 -0800 webmaster@mediligence.com (Patrick Driscoll) FeedForAll v2.0 (2.0.2.9) http://www.feedforall.com http://www.mediligence.com/rss/MMD_logo_144x63pxl.jpg Interventional Cardiology, from MedMarket Diligence, LLC http://mediligence.com/rpt/interventional-cardiology.htm Coverage of technology and clinical practice developments in interventional cardiology, from the Market and Technology Reports analysis and other ongoing research from MedMarket Diligence, LLC 144 63 Coronary Artery Disease Treatment Alternatives advanced medical technologies blog, we note the treatment options and even the treatment "map" that represents the current and future alternatives for CAD.

To hammer the point, It is worth noting that one radical alternative to stenting and bypass for CAD -- the dyslipidemia treatment by Esperion Therapeutics' ETC-1002, has advanced to Phase I trials this week.

Worldwide Market for Drug-Eluting, Bare Metal and Other Coronary Stents, 2008-2017. Report #C245

For additional information, contact Patrick Driscoll, patrick at mediligence dot com, tel: 949-859-3401.

Tags: stent, drug-eluting, interventional cardiology, restenosis]]> http://mediligence.com/rpt/rpt-c245.htm reports@mediligence.com (Patrick Driscoll) Business/Healthcare/Products_and_Services/ http://mediligence.com/rpt/rpt-c245.htm Mon, 16 Nov 2009 12:00:10 -0800 MedMarket Diligence, LLC Coronary Stent Sales Globally Driven by Some Big Local Market Differences report from MedMarket Diligence on drug-eluting, bare metal and soon-to-emerge bioabsorbable coronary stents, and other anti-restenosis technologies.

Differences in the volume and the growth rates of coronary stent sales stem from some anticipated local market variables, like demographics, and other variables in the unique market dynamics of each geography.

The advance medical technologies blog highlights some of the findings in the MedMarket Diligence report #C245 on coronary stents.

Worldwide Market for Drug-Eluting, Bare Metal and Other Coronary Stents, 2008-2017. Report #C245

For additional information, contact Patrick Driscoll, patrick at mediligence dot com, tel: 949-859-3401.

Tags: stent, drug-eluting, interventional cardiology, restenosis]]> http://mediligence.com/blog/2009/10/19/coronary-stents-big-differences-in-adoption-globally/ reports@mediligence.com (Patrick Driscoll) Business/Healthcare/Products_and_Services/ http://mediligence.com/blog/2009/10/19/coronary-stents-big-differences-in-adoption-globally/ Wed, 21 Oct 2009 22:40:01 -0700 MedMarket Diligence, LLC Interventional and surgical technologies knocking elbows
The advanced medical technologies blog highlights developments and markets in surgical and interventional technologies.

See recent surgical and interventional technology reports from MedMarket Diligence:

Worldwide Wound Management Market, 2008-2017. Report #S247
Worldwide Market for Drug-Eluting, Bare Metal and Other Coronary Stents, 2008-2017. Report #C245
Worldwide Surgical Sealants, Glues, Wound Closure and Anti-adhesion Markets, 2009-2013. Report #S175
Ablation Technologies Worldwide Market, 2008-2017. Report #A125

For additional information, contact Patrick Driscoll, patrick at mediligence dot com, tel: 949-859-3401.

Tags: surgery, surgical, interventional, wound management, dressings, bandages, negative pressure, non-adherent, decubitus ulcer, stasis ulcer, surgical sealant, surgical glue, stent.]]> http://mediligence.com/blog/category/surgery/ reports@mediligence.com (Patrick Driscoll) Business/Healthcare/Products_and_Services/ http://mediligence.com/blog/2009/10/11/in-the-coronary-stent-market-many-preconceived-notions-miss-the-mark/ Wed, 14 Oct 2009 09:51:00 -0700 MedMarket Diligence, LLC For Now, Drug-Eluting Stents Dominate the Coronary Stent Market "Worldwide Coronary Stents 2009," from MedMarket Diligence.

Currently, drug-eluting stents (DES) command 60% of typical markets for coronary stents and, in some markets like China, the share is much higher.  Growth in the market for DES, at over 7%, is more than twice what it is for bare metal stents, since DES have demonstrated, through anti-restenosis, the ability to considerably reduced the need for repeat revascularization. The market for coronary stents will therefore continue to grow, penetrating deeper into bare metal stent markets and furthering the erosion of demand for the more invasive surgical alternative, coronary artery bypass grafting.

"The number of active companies and the size and growth of the market for coronary stents speaks to the intensity of development," says Patrick Driscoll of MedMarket Diligence, publisher of the report, 'Worldwide Coronary Stents Market, 2009'.  At least 75 companies are active in this arena, with current products on the market or at various stages of development.  Few avenues are being overlook in development, from stent material types, stent surface technology, drug-coating alternatives, drug-coating processes and others.

Development of stent alternatives also includes bioabsorbable stents, which may be the likely successor to drug-eluting stents if they achieve the goal of providing revascularization with markedly better long-term clinical outcomes. Bioabsorbales under development may well enter some markets as soon as two years from now.

Moreover, the premise of drug-eluting stents is being challenged through alternatives like drug-eluting balloon angioplasty and other device and non-device alternatives.

The MedMarket Diligence report #C245 is described at http://www.mediligence.com/rpt/rpt-c245.htm and details the worldwide market for the use of alternative stent devices in the treatment of coronary artery disease.  The report assesses the treatment of coronary artery disease by alternative treatment methodologies (percutaneous intervention with or without stenting, coronary artery bypass grafting alternatives and other medical/surgical treatment options), with estimated current/forecast caseload across treatment types.

The report provides full year (actual) 2008 market size and share data, with forecast market data to 2017, for the U.S., Europe, Asia/Pacific and Rest of World.

The report details currently approved coronary stents, providing data on current and forecast impact on the market.  The report also details the current state of product development in bare stents, drug-coated or drug-eluting stents and bioabsorbable stents in coronary applications and details the products under development, the anticipated timeline and impact of their market introduction.  The report assesses the current and ten-year forecast global market for coronary stents, with segmentation by U.S., Europe, Asia/Pacific and Rest of World.  The report provides competitor market shares by these geographic regions.  The leading and key emerging coronary stent manufacturers are profiled with current product offerings, development status and market strengths/advantages.

The report is described at this link.  The report may be ordered for immediate download online.

MedMarket Diligence provides tactical decision-making solutions on medical technology to the medical products and investment industries. The company publishes dedicated Reports on medical technology markets and offers the Medtech Startups Database on hundreds of newly founded medtech companies.

Tags: stents, drug eluting, drug-coated, angioplasty, PTCA]]> http://www.prlog.org/10337003 reports@mediligence.com (Patrick Driscoll) Business/Healthcare/Products_and_Services/ http://www.prlog.org/10337003 Wed, 9 Sep 2009 13:41:09 -0700 MedMarket Diligence, LLC Competition Remains High in Coronary Stent Market, According to New Global Market Report The global coronary stent market faces continued growth, development and competition from a wide range of technology types and competitors. The market is detailed in a new report from MedMarket Diligence.

Since the advent of coronary stents, followed by the emergence of drug eluting stents, the field of stents in the treatment of coronary artery disease has been characterized by aggressive development of new technologies, from minor changes in strut design and drug-coating processes to more radical thinking of the kind that lead from bare metal stents to drug-eluting stents. The coronary stent market is currently in a phase in which the clinical and market success of drug-eluting stents introduced six years ago has stimulated innovation toward emergence of new drug-eluting stent types from many competitors. While the less invasiveness of coronary stents (delivered percutaneously) and outcomes of drug-eluting stents that are nearly comparable to coronary bypass are enabling coronary stents to expand the absolute market of coronary stents by capturing caseload from CABG, the market once dominated by Johnson & Johnson's Cordis division is now becoming progressively fragmented with new competitors. The market is now facing new challenges with the pending emergence of bioabsorbable stents, drug-eluting balloons and other competitive alternatives to the established stent market.

The global market for coronary stents, examining the products, technologies, companies and worldwide markets for bare metal, drug-eluting and other coronary stents, is the subject of MedMarket Diligence's report #C245, "Worldwide Coronary Stents 2008-2017" (published May 2009). See link.

"The nature of coronary artery disease, as a major source of morbidity and mortality worldwide, and the support (including especially reimbursement) that treatments receive in the healthcare arena, is a major impetus for technology development," says Patrick Driscoll of MedMarket Diligence. According to Driscoll, there are no fewer than 75 active companies developing and marketing coronary stents and competitive technologies, and the market is likely to become even more consolidated unless new, innovative anti-restenosis technologies are introduced that demonstrate profound clinical advantages over existing options.

The market is facing the emergence, in particular, of bioabsorbable stents, which have demonstrated their potential to provide the necessary anti-restenotic benefit following percutaneous intervention (e.g., angioplasty), then "simply" dissolve and be absorbed at six months or later. Such a device has the potential to eliminated longer term biocompatibility and otherwise inflammatory risk associated with permanently implanted stents.  Bioabsorbable stents, too, may be bare or, more likely, containing drug coatings.

The MedMarket Diligence report details the worldwide market for the use of alternative stent devices (cardiac stents or heart stents) in the treatment of coronary artery disease. The report assesses the treatment of coronary artery disease by alternative treatment methodologies (percutaneous intervention with or without stenting, coronary artery bypass grafting alternatives and other medical/surgical treatment options), with estimated current/forecast caseload across treatment types.

The report details currently approved coronary stents, providing data on current and forecast impact on the market. The report also details the current state of product development in bare stents, drug-coated or drug-eluting stents and bioabsorbable stents in coronary applications and details the products under development, the anticipated timeline and impact of their market introduction. The report assesses the current and ten-year forecast global market for coronary stents, with segmentation by U.S., Europe, Asia/Pacific and Rest of World. The report provides competitor market shares by these geographic regions. The leading and key emerging coronary stent manufacturers are profiled with current product offerings, development status and market strengths/advantages.

The report is described at this link.  The report may be ordered for immediate download online.

MedMarket Diligence provides tactical decision-making solutions on medical technology to the medical products and investment industries. The company publishes dedicated Reports on medical technology markets and offers the Medtech Startups Database on hundreds of newly founded medtech companies.

Tags: stents, drug eluting, drug-coated, angioplasty, PTCA]]> http://www.prlog.org/10327393 reports@mediligence.com (Patrick Driscoll) Business/Healthcare/Products_and_Services/ http://www.prlog.org/10327393 Mon, 31 Aug 2009 15:55:46 -0700 MedMarket Diligence, LLC Worldwide Market for Drug-Eluting, Bare and Other Coronary Stents, 2008-2017
The report details currently approved coronary stents, providing data on current and forecast impact on the market. The report also details the current state of product development in bare stents, drug-coated or drug-eluting stents and bioabsorbable stents in coronary applications and details the products under development, the anticipated timeline and impact of their market introduction. The report assesses the current and ten-year forecast global market for coronary stents, with segmentation by U.S., Europe, Asia/Pacific and Rest of World. The report provides competitor market shares by these geographic regions. The leading and key emerging coronary stent manufacturers are profiled with current product offerings, development status and market strengths/advantages.

MedMarket Diligence report #C245: "Worldwide Coronary Stents Market, 2008-2017" (published May 2009). The report may be purchased for immediate download online or may be ordered via order form.

Tags: stents, drug eluting, drug-coated, angioplasty, PTCA]]> http://www.mediligence.com/rpt/rpt-c245.htm reports@mediligence.com (Patrick Driscoll) Business/Healthcare/Products_and_Services/ 29FCBC47-E0E9-4A32-80CA-9E75E916CA77 Sat, 15 Aug 2009 10:46:58 -0700 MedMarket Diligence, LLC Coronary stents and variable geographic adoption
The advanced medical technologies blog highlights the geographic growth in the use and market for drug-eluting stents versus bare metal stents, with variable opportunity in major geographic areas.

Global market size and growth in coronary stents are the subject of the MedMarket Diligence report #C245, "Worldwide Coronary Stents Market, 2008-2017" (published May 2009). The report may be purchased for immediate download online or may be ordered via order form.

Tags: stents, drug eluting, drug-coated, angioplasty, PTCA]]> http://mediligence.com/blog/2009/08/12/coronary-stents-and-variable-geographic-adoption/ reports@mediligence.com (Patrick Driscoll) Business/Healthcare/Products_and_Services/ 748911EB-8A4C-4AC8-B945-AFDF56123DF8 Thu, 13 Aug 2009 13:56:37 -0700 MedMarket Diligence, LLC Drug/coating alternatives under developments in the market for coronary stents advanced medical technologies highlights drugs/coatings in development for drug-eluting stents.

Global market size and growth in coronary stents are the subject of the MedMarket Diligence report #C245, "Worldwide Coronary Stents Market, 2008-2017" (published May 2009). The report may be purchased for immediate download online or may be ordered via order form.

Tags: stents, drug eluting, drug-coated, angioplasty, PTCA]]> http://mediligence.com/blog/2009/08/09/drugcoating-alternatives-in-drug-eluting-stent-development/ reports@mediligence.com (Patrick Driscoll) Business/Healthcare/Products_and_Services/ http://mediligence.com/blog/2009/08/09/drugcoating-alternatives-in-drug-eluting-stent-development/ Sun, 9 Aug 2009 09:14:19 -0700 MedMarket Diligence, LLC Drug-eluting stent market, geographic growth
The advanced medical technologies blog highlights the geographic growth in the use and market for drug-eluting stents, with variable opportunity in major geographic areas.

Global market size and growth in coronary stents are the subject of the MedMarket Diligence report #C245, "Worldwide Coronary Stents Market, 2008-2017" (published May 2009). The report may be purchased for immediate download online or may be ordered via order form.

(Twitter users search .twitter.comfor MedMarket coupon options.)

Tags: stents, drug eluting, drug-coated, angioplasty, PTCA]]> http://mediligence.com/blog/2009/07/26/drug-eluting-stent-market-geographic-growth/ reports@mediligence.com (Patrick Driscoll) Business/Healthcare/Products_and_Services/ 0D8F50B5-2F8B-4283-A470-777D74FA51F9 Sun, 26 Jul 2009 09:46:48 -0700 MedMarket Diligence, LLC Coronary Stents: Emerging New Stent Alternatives

Pericardium covered
Radioactive stents
Biomimetic coatings
Hydrophilic coatings
Titanium-nitride-oxygen coatings
Genetically-engineered bioactive coating
Endothelial cell-stimulating coatings
Synthetic graft stent alternative
Nano-polymer coatings
Stent with embolic protection

While drug-eluting stents have gained solid and growing shares of the worldwide stent market, interventional cardiologists and healthcare systems have demonstrated considerable propensity to shift toward or away from different stent alternatives based on available data --- even incomplete data, which was clearly the case with late-stage thrombosis putting a temporary pinch on DES sales (see also recent data on Xtent's Custom NX that may just pull Xtent back from the brink of shutting down). Aggressive innovators in stent technologies may be rewarded with substantial caseload if their designs can demonstrate even nominal improvements over available stents, a point embraced as readily by the market leaders as by one-device companies.

Stent technologies and markets globally are the subject of the MedMarket Diligence report #C245, "Worldwide Coronary Stents Market, 2008-2017" (published May 2009). The report may be purchased for immediate download online or may be ordered via order form.

Tags: stents, drug eluting, drug-coated, angioplasty, PTCA]]> http://mediligence.com/rpt/rpt-c245.htm#Other_Types_of_Stents reports@mediligence.com (Patrick Driscoll) Business/Healthcare/Products_and_Services/ B92F9A1E-B255-474F-B137-7C8CBCF3AED2 Wed, 8 Jul 2009 08:24:52 -0700 MedMarket Diligence, LLC Stents: The ideal treatment of coronary artery disease? blog, drawing on the MedMarket Diligence global stent market report #C245, details the major stent (and other anti-restenosis) technology on the market and in development.

The "advanced medical technologies" blog breaks down the principal stent material types on the market and in development, with data drawn from the May 2009 report on coronary stents.

MedMarket Diligence has recently published (May 2009) report #C245, "Worldwide Coronary Stents Market, 2008-2017". The report may be purchased for immediate download online or may be ordered via order form.

Tags: stents, drug eluting, drug-coated, angioplasty, PTCA]]> http://mediligence.com/blog/2009/06/15/coronary-stent-types-drug-eluting-bare-metal-others/ reports@mediligence.com (Patrick Driscoll) Business/Healthcare/Products_and_Services/ http://mediligence.com/blog/2009/06/15/coronary-stent-types-drug-eluting-bare-metal-others/ Mon, 15 Jun 2009 14:45:13 -0700 MedMarket Diligence, LLC Cardiology/Cardiovascular Device Technologies Drive Medtech Startups
A review of companies formed in recent years and captured in the Medtech Startups Database illustrates that the cardiology/cardiovascular arena is among the most prolific in medtech startup formation. In less than five years, over one hundred (100) companies have been founded with a focus on either cardiology diagnostics or therapeutics.

Interventional cardiology in particular, including the clinical procedures of angioplasty, stenting and related procedures, have contributed to markets with an aggregate value near $10 billion worldwide.

The Medtech Startups Database is an online subscription database of medical device and competing or complementary technology companies, with details on company area(s) of focus, products/technology status, principals and other contact details. The database is described here.

In the field of cardiology, MedMarket Diligence has recently published (May 2009) report #C245, "Worldwide Coronary Stents Market, 2008-2017". The report may be purchased for immediate download online or may be ordered via order form.

Tags: stents, drug eluting, drug-coated, angioplasty, PTCA]]> http://mediligence.com/startups-db.htm#Clinical_and_technology reports@mediligence.com (Patrick Driscoll) Business/Healthcare/Products_and_Services/ http://mediligence.com/startups-db.htm#Clinical_and_technology Tue, 9 Jun 2009 12:59:34 -0700 MedMarket Diligence, LLC Least invasive (totally endoscopic) coronary artery bypass and other points on the coronary artery disease treatment timeline

Coronary artery bypass is developed, dramatically increasing quality of life for a coronary artery disease, where no real alternative existed previously.
Percutaneous transluminal coronary angioplasty is developed, providing a less invasive means to provide reperfusion of the myocardium, but needs to be repeated occasionally due to restenosis and mitigating the "less invasive" quality of PTCA.
Stents are developed to maintain patency following angioplasty, reducing but not eliminated the need for repeat procedures
Drug-eluting stents (DES) are developed that provide anti-restenosis and maintain patency and again reduce the need for repeat procedures
Occurrence of late stage thrombosis associated with DES emerges, causing a momentary lull in stent sales, but proving temporary, or at least limited to a small cohort.
Bioabsorbable stents are under development to improve DES outcomes
Other developments are in progress (drug-eluting balloons, HDL therapy, gene therapy cell therapy)
"Less invasive" (MIDCAB) and "least invasive" (TECAB) options for coronary bypass are under development to remove the invasiveness of bypass and make it more competitive with percutaneous procedures.

This timeline has many more future chapters on it, but what follows the development of minimally invasive direct coronary artery bypass (MIDCAB) or totally endoscopic coronary artery bypass (TECAB ) is highly unlikely to be the  demise of drug-eluting stents.

A post on the advanced medical technologies blog provides a description and brief video on TECAB. .

See the May 2009 report #C245, "Worldwide Coronary Stents Market, 2008-2017", which covers alternative treatments, like TECAB, for treatment of coronary artery disease.  The report may be purchased for immediate download online or may be ordered via order form.

Tags: stents, drug eluting, drug-coated, angioplasty, PTCA]]> http://mediligence.com/blog/2009/06/08/totally-endoscopic-coronary-artery-bypass-grafting/ reports@mediligence.com (Patrick Driscoll) Business/Healthcare/Products_and_Services/ http://mediligence.com/blog/2009/06/08/totally-endoscopic-coronary-artery-bypass-grafting/ Mon, 8 Jun 2009 21:35:37 -0700 Percutaneous implantation of a coronary stent advanced medical technologies blog in both text and a brief video.

See the May 2009 report #C245, "Worldwide Coronary Stents Market, 2008-2017."  The report may be purchased for immediate download online or may be ordered via order form.

Tags: stents, drug eluting, drug-coated, angioplasty, PTCA]]> http://mediligence.com/blog/2009/06/02/coronary-stent-implantation/ reports@mediligence.com (Patrick Driscoll) Business/Healthcare/Products_and_Services/ http://mediligence.com/blog/2009/06/02/coronary-stent-implantation/ Wed, 3 Jun 2009 14:46:08 -0700 Coronary artery disease treatment alternatives run a gamut of techniques, technologies
The advanced medical technologies blog details the range of options in place and under continued development as the technologies evolve and caseload shifts toward those providing optimal performance.

See the May 2009 report #C245, "Worldwide Coronary Stents Market, 2008-2017."  The report may be purchased for immediate download online or may be ordered via order form.

Tags: stents, drug eluting, drug-coated, angioplasty, PTCA]]> http://mediligence.com/blog/2009/05/27/coronary-artery-treatment-options/ reports@mediligence.com (Patrick Driscoll) Business/Healthcare/Products_and_Services/ http://mediligence.com/blog/2009/05/27/coronary-artery-treatment-options/ Wed, 27 May 2009 13:10:59 -0700 Taking the lead in the coronary stent market: U.S.? Europe? China?
But the dynamic is different in the market for coronary stents.  And it has much less to do with technology migration than market size.

The advanced medical technologies blog, drawing on the May 2009 report #C245, "Worldwide Coronary Stents Market, 2008-2017," explores the geographic impact of different coronary stent types.

Report #C245, "Worldwide Market for Drug-Eluting, Bare and Other Coronary Stents, 2008-2017."  The report, described here, may be purchased for immediate download (and with limited time discount) online or may be ordered via order form.

Tags: stents, drug eluting, drug-coated, angioplasty, PTCA]]> http://mediligence.com/blog/2009/05/11/taking-the-lead-in-the-drug-eluting-stent-market-china/ reports@mediligence.com (Patrick Driscoll) Business/Healthcare/Products_and_Services/ http://mediligence.com/blog/2009/05/11/taking-the-lead-in-the-drug-eluting-stent-market-china/ Sun, 24 May 2009 16:20:47 -0700 SYNTAX: Percutaneous Coronary Intervention (PCI) compared to Coronary Artery Bypass Grafting (CABG)
The advanced medical technologies blog reviews the SYNTAX trial (and notes the reviews of clinical trials detailed in the MedMarket Diligence Report #C245, "Worldwide Market for Drug-Eluting, Bare and Other Coronary Stents, 2008-2017."  The report, described here, may be purchased online or via order form.

Tags: stents, drug eluting, drug-coated, angioplasty, PTCA]]> http://mediligence.com/blog/2009/05/24/syntax-pci-cabg/ reports@mediligence.com (Patrick Driscoll) Business/Healthcare/Products_and_Services/ http://mediligence.com/blog/2009/05/24/syntax-pci-cabg/ Sun, 24 May 2009 12:15:23 -0700 Worldwide Coronary Stents Market .
The advanced medical technologies blog highlights the three major sectors of coronary stents:  drug-eluting, bare and bioresobable.

Report #C245, "Worldwide Market for Drug-Eluting, Bare and Other Coronary Stents, 2008-2017."  The report, described here, may be advance purchased (with discount on paid orders) online or via order form.

Tags: stents, drug eluting, drug-coated, angioplasty, PTCA]]> http://mediligence.com/blog/2009/04/21/worldwide-coronary-stents-market/ reports@mediligence.com (Patrick Driscoll) Business/Healthcare/Products_and_Services/ http://mediligence.com/blog/2009/04/21/worldwide-coronary-stents-market/ Sun, 24 May 2009 11:39:39 -0700 Drug-Eluting Balloons as Alternative to Combined Angioplasty/Stenting (MedMarket Diligence) recent review of drug-eluting balloons, drawn from the forthcoming (April) publication of the MedMarket Diligence Report #C245, "Worldwide Market for Drug-Eluting, Bare and Other Coronary Stents, 2008-2017."

Tags: stents, drug eluting, drug-coated, angioplasty, PTCA]]> http://mediligence.com/blog/2009/05/07/beyond-drug-eluting-and-bioresorbable-stents/ reports@mediligence.com (Patrick Driscoll) Business/Healthcare/Products_and_Services/ http://mediligence.com/blog/2009/05/07/beyond-drug-eluting-and-bioresorbable-stents/ Sat, 23 May 2009 10:13:43 -0700 Coronary Stents Market Worldwide Holds Big Incentive for Growth, Opportunity in Novel Technologies, According to New MedMarket Diligence Report
Report #C245, "Worldwide Market for Drug-Eluting, Bare and Other Coronary Stents, 2008-2017."  The report, described here, may be purchased for immediate download (and with limited time discount) online or may be ordered via order form.

Tags: stents, drug eluting, drug-coated, angioplasty, PTCA]]> http://mediligence.com/PR/PR2009-05-04.htm reports@mediligence.com (Patrick Driscoll) Business/Healthcare/Products_and_Services/ http://mediligence.com/PR/PR2009-05-04.htm Fri, 22 May 2009 09:24:20 -0700